Metabolic effects of the obstructive sleep apnea syndrome and cardiovascular risk
Metabolic effects of the obstructive sleep apnea syndrome and cardiovascular risk
复制标题
DOI：
10.1080/13813450802307451
复制
发表时间：
2008-01-01
影响因子：
3
通讯作者：
Zito, Anna
中科院分区：
文献类型：
--
作者：
Bonsignore, Maria Rosaria;Zito, Anna
阻塞性睡眠呼吸暂停综合征（OSAS）的特点是睡眠时上呼吸道塌陷，反复出现呼吸暂停，间歇性低氧血症和白天嗜睡。OSAS通常与肥胖有关，由于全球肥胖流行，其患病率预计将上升。OSAS与心血管风险增加相关，睡眠期间使用鼻腔持续气道正压通气（nCPAP）治疗可使心血管风险正常化，提示OSAS在加速动脉粥样硬化中具有独立作用。胰岛素抵抗（IR）和代谢综合征（MetS）常见于OSAS患者，但OSAS与肥胖的相对作用尚不清楚。OSAS和MetS都可能通过多种机制（低氧血症、睡眠中断、交感神经系统激活、炎症激活）对心血管系统产生负协同作用。除了nCPAP治疗外，治疗肥胖和MetS的药物干预可以改善OSAS的心血管预防。
The obstructive sleep apnea syndrome (OSAS) is characterized by collapse of the upper airway during sleep, recurring apneas, intermittent hypoxemia and daytime somnolence. OSAS is often associated with obesity, and its prevalence is expected to rise due to the obesity epidemics worldwide. OSAS is associated with increased cardiovascular risk which appears to be normalized by treatment with nasal continuous positive airway pressure (nCPAP) during sleep, suggesting an independent role of OSAS in accelerating atherosclerosis. Insulin resistance (IR) and the metabolic syndrome (MetS) are often found in OSAS patients, but the relative role played by OSAS and obesity is still unclear. Both OSAS and MetS may exert negative synergistic effects on the cardiovascular system through multiple mechanisms (hypoxemia, sleep disruption, activation of the sympathetic nervous system, inflammatory activation). Besides nCPAP treatment, pharmacologic interventions to treat obesity and the MetS could improve cardiovascular prevention in OSAS.